Publication:
Characterization of solid lipid nanoparticles containing caffeic acid and determination of its effects on MCF-7 cells

dc.contributor.authorDikmen, Gökhan
dc.contributor.authorGenç, Lütfi
dc.contributor.buuauthorGüney, Gamze
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentTıbbi Biyoloji Ana Bilim Dalı
dc.contributor.orcid0000-0002-2088-9914
dc.contributor.researcheridAAB-6011-2022
dc.contributor.scopusid54396977600
dc.date.accessioned2024-03-14T12:53:13Z
dc.date.available2024-03-14T12:53:13Z
dc.date.issued2015
dc.description.abstractMany anticancer drugs that are currently used in cancer treatment are natural products or their analogues by structural modification. Caffeic acid (3, 4-dihydroxycinnamic acid; CA) is classified as hydroxycinnamic acid and has a variety of potential pharmacological effects, including antioxidant, immunomodulatory and anti-inflammatory activities. As a drug carrier, solid lipid nanoparticles (SLNs) introduced to improve stability, provide controlled drug release, avoid organic solvents and are obtained in small sizes. In this study, we developed solid lipid nanoparticles incorporating with caffeic acid using hot homogenization method. Caffeic acid loaded solid lipid nanoparticles were characterized regarding particle size, zeta potential, drug entrapment efficiency, drug release, scanning electron microscopy (SEM) and FT-IR. The effects of caffeic acid loaded solid lipid nanoparticles on MCF-7 cells were determined by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-dimethyl tetrazolium bromide (MTT) test and Annexin V-PI analysis. As a result, solid lipid nanoparticles could potentially be used for the delivery of caffeic acid and solid lipid nanoparticles formulation enhanced the effects of caffeic acid on MCF-7 cells. Some relevant patents are also referred in this article.
dc.identifier.citationDikmen, G. vd. (2015). "Characterization of solid lipid nanoparticles containing caffeic acid and determination of its effects on MCF-7 cells". Recent Patents on Anti-Cancer Drug Discovery, 10(2), 224-232.
dc.identifier.doihttps://doi.org/10.2174/1574892810666150115124413
dc.identifier.endpage232
dc.identifier.issn1574-8928
dc.identifier.issn2212-3970
dc.identifier.issue2
dc.identifier.pubmed25619199
dc.identifier.scopus2-s2.0-84930883833
dc.identifier.startpage224
dc.identifier.urihttps://www.eurekaselect.com/article/64565
dc.identifier.urihttps://hdl.handle.net/11452/40412
dc.identifier.volume10
dc.identifier.wos000354364700010
dc.indexed.scopusScopus
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherBentham Science Publisher
dc.relation.collaborationYurt içi
dc.relation.journalRecent Patents on Anti-Cancer Drug Discovery
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectOncology
dc.subjectPharmacology & pharmacy
dc.subjectApoptosis
dc.subjectCaffeic acid (CA)
dc.subjectCancer
dc.subjectCharacterization
dc.subjectDrug delivery systems
dc.subjectSolid lipid nanoparticles (SLNs)
dc.subjectPhenethyl ester suppresses
dc.subjectMicroscale drug particles
dc.subjectNatural-products
dc.subjectCancer cells
dc.subjectSLN
dc.subjectImmobilization
dc.subjectProliferation
dc.subjectCytotoxicity
dc.subjectMetastasis
dc.subjectInhibition
dc.subject.emtreeCaffeic acid
dc.subject.emtreeLipocortin 5
dc.subject.emtreeSolid lipid nanoparticle
dc.subject.emtreeAntineoplastic agent
dc.subject.emtreeCaffeic acid
dc.subject.emtreeCaffeic acid derivative
dc.subject.emtreeDelayed release formulation
dc.subject.emtreeDrug carrier
dc.subject.emtreeLipid
dc.subject.emtreeNanoparticle
dc.subject.emtreeApoptosis
dc.subject.emtreeArticle
dc.subject.emtreeBreast cancer
dc.subject.emtreeControlled drug release
dc.subject.emtreeControlled study
dc.subject.emtreeDrug entrapment
dc.subject.emtreeDrug formulation
dc.subject.emtreeDrug stability
dc.subject.emtreeHot homogenization method
dc.subject.emtreeHuman
dc.subject.emtreeHuman cell
dc.subject.emtreeInfrared spectroscopy
dc.subject.emtreeMCF 7 cell line
dc.subject.emtreeMTT assay
dc.subject.emtreeParticle size
dc.subject.emtreePhoton correlation spectroscopy
dc.subject.emtreePriority journal
dc.subject.emtreeProcedures
dc.subject.emtreeScanning electron microscopy
dc.subject.emtreeZeta potential
dc.subject.emtreeBreast neoplasms
dc.subject.emtreeChemistry
dc.subject.emtreeDelayed release formulation
dc.subject.emtreeDrug delivery system
dc.subject.emtreeFemale
dc.subject.emtreeMedicinal chemistry
dc.subject.emtreePatent
dc.subject.emtreePathology
dc.subject.meshAntineoplastic agents
dc.subject.meshBreast neoplasms
dc.subject.meshCaffeic acids
dc.subject.meshChemistry, pharmaceutical
dc.subject.meshDelayed-action preparations
dc.subject.meshDrug carriers
dc.subject.meshDrug compounding
dc.subject.meshDrug delivery systems
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshLipids
dc.subject.meshMCF-7 cells
dc.subject.meshMicroscopy, electron, scanning
dc.subject.meshNanoparticles
dc.subject.meshParticle size
dc.subject.meshPatents as topic
dc.subject.meshSpectroscopy, fourier transform infrared
dc.subject.scopusNanocrystal; Tristearin; Polydispersity
dc.subject.wosOncology
dc.subject.wosPharmacology & pharmacy
dc.titleCharacterization of solid lipid nanoparticles containing caffeic acid and determination of its effects on MCF-7 cells
dc.typeArticle
dc.wos.quartileN/A
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Tıbbi Biyoloji Ana Bilim Dalı
local.indexed.atPubMed
local.indexed.atWOS
local.indexed.atScopus

Files

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: